+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease

Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease

Annals of Neurology 48(1): 27-38

With the ultimate goal of developing safe and effective in vivo gene therapy for the treatment of Canavan disease and other neurological disorders, we developed a non-viral lipid-entrapped, polycation-condensed delivery system (LPD) for central nervous system gene transfer, in conjunction with adeno-associated virus (AAV)-based plasmids containing recombinant aspartoacylase (ASPA). The gene delivery system was tested in healthy rodents and primates, before proceeding to preliminary studies in 2 children with Canavan disease. Toxicity and expression testing was first carried out in human 293 cells, which demonstrated effective transduction of cells and high levels of functional ASPA activity. We performed in vivo toxicity and expression testing of LPD/pAAVaspa and LPD/pAAVlac in rodents, which demonstrated widespread gene expression for more than 10 months after intraventricular delivery, and local expression in deep brain nuclei and white matter tracts for more than 6 months after intraparenchymal injections, with no significant adverse effects. We also performed intraventricular delivery of LPD/pAAVaspa to 2 cynomologous monkeys, with 2 additional monkeys receiving LPD and saline controls. None of the monkeys demonstrated significant adverse effects, and at 1 month the 2 LPD/pAAVaspa monkeys were positive for human ASPA transcript by reverse transcriptase polymerase chain reaction of brain tissue punches. Finally, we performed the first in vivo gene transfer study for a human neurodegenerative disease in 2 children with Canavan disease to assess the in vivo toxicity and efficacy of ASPA gene delivery. Our results suggest that LPD/pAAVaspa is well tolerated in human subjects and is associated with biochemical, radiological, and clinical changes.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 010204477

Download citation: RISBibTeXText

PMID: 10894213

DOI: 10.1002/1531-8249(200007)48:1<27::aid-ana6>3.0.co;2-6

Related references

Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Journal of Gene Medicine 2(3): 165-175, 2000

Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease. Brain Research. Molecular Brain Research 107(2): 176-182, 2002

Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease. Brain Research. Molecular Brain Research 135(1-2): 112-121, 2005

Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Molecular Therapy 7(5 Pt 1): 580-587, 2003

Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease. Current Pharmacogenomics 2(1): 13-20, 2004

Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Research 1148: 1-14, 2007

A Novel Mutation in Aspartoacylase Gene; Canavan Disease. Iranian Journal of Child Neurology 9(4): 54-57, 2015

A novel aspartoacylase (ASPA) gene mutation in Canavan disease. Fetal and Pediatric Pathology 31(4): 236-239, 2012

Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Journal of Tropical Pediatrics 54(3): 208-210, 2007

A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Genetic Counseling 23(1): 9-12, 2012

A partial deletion of the aspartoacylase gene is the cause of Canavan disease in a family from Mexico. Journal of Medical Genetics 38(3): E9, 2001

Aspartoacylase gene, protein, and methods of screening for mutations associated with canavan disease. Official Gazette of the United States Patent & Trademark Office Patents 1203(3): 2201, Oct 21, 1997

Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan disease. Advances in Experimental Medicine and Biology 576: 165-73; Discussion 361-3, 2006

The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients. Journal of Inherited Metabolic Disease 22(4): 531-534, 1999

Identification of a novel 200-kb deletion spanning the 5-end of the aspartoacylase gene in a family with Canavan disease. American Journal of Human Genetics 67(4 Supplement 2): 295, 2000